Detalles de la búsqueda
1.
Outcomes of Salvage Surgery Versus Non-Salvage Surgery for Initially Unresectable Hepatocellular Carcinoma After Conversion Therapy with Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Antibody: A Multicenter Retrospective Study.
Ann Surg Oncol
; 31(5): 3073-3083, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38316732
2.
Should associating liver partition and portal vein ligation for staged hepatectomy be applied to hepatitis B virus-related hepatocellular carcinoma patients with cirrhosis? A multi-center study.
HPB (Oxford)
; 24(12): 2175-2184, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36280426
3.
ASO Author Reflections: Impact of Salvage Surgery in Unresectable Hepatocellular Carcinoma After Conversion Therapy: Should it be Recommended?
Ann Surg Oncol
; 31(5): 3100-3101, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38300403
4.
The TAE score predicts prognosis of unresectable HCC patients treated with TACE plus lenvatinib with PD-1 inhibitors.
Hepatol Int
; 18(2): 651-660, 2024 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-38040945
5.
Long-term surgical outcomes of bile duct tumor thrombus versus portal vein tumor thrombus for hepatocellular carcinoma: a propensity score matching analysis.
Front Oncol
; 14: 1372123, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38628666
6.
Transarterial Chemoembolization Plus Lenvatinib and PD-1 Inhibitors for Hepatocellular Carcinoma with Main Trunk Portal Vein Tumor Thrombus: A Multicenter Retrospective Study.
J Hepatocell Carcinoma
; 10: 1799-1811, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37850080
7.
Surgical outcomes of hepatocellular carcinoma with extrahepatic bile duct tumor thrombus: a multicenter study.
Front Oncol
; 13: 1291479, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-38111530
Resultados
1 -
7
de 7
1
Próxima >
>>